SARS‐CoV‐2 Vaccination Rates and Uptake of Tixagevimab‐Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients
Clinical Transplantation · 2024-07 · 38 (7)
DOI: 10.1111/ctr.15407 ↗At a glance
Journal article in Clinical Transplantation, published online on 2024-07-21. Written by Christopher A Reis and 2 co-authors. Institution: Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA. Major MEDLINE topics: COVID-19, Organ Transplantation, COVID-19 Vaccines, SARS-CoV-2. Cited 1 times so far (Crossref); 15 references.
Abstract (original language)
Introduction
There is a lack of data regarding SARS‐CoV‐2 vaccination rates and tixagevimab‐cilgavimab (TC) uptake among pediatric solid organ transplant recipients. The purpose of our study was to assess these rates. Materials and Methods We reviewed vaccination records of pediatric recipients of heart, kidney, and liver transplants at Mayo Clinic, Rochester, MN, who received a transplant between January 2011 and December 2021. All SARS‐CoV‐2 vaccines and doses of TC received on or before September 1, 2022, the date of approval of the bivalent SARS‐CoV2 vaccine, were included. We also assessed whether patients had been seen by an infectious diseases physician (ID) in the preceding 6 months.
Results
Our study included 110 patients: 47 kidney, 36 heart, and 27 liver transplant recipients. All vaccine doses recorded were monovalent SARS‐CoV‐2 vaccines. Sixty‐eight (61.8%) patients received at least one vaccine. This varied by age group, with f of ≥12 years olds, 40.9% of 5–11 year olds and 14.3% of under 5 year olds ( p = 0.001). Seven patients (6.4%) were up‐to‐date (UTD) for age. There was no difference in UTD status by organ type ( p = 0.335). Patients who saw ID were significantly more likely to be UTD (13.2% versus 2.8%; p = 0.047). Among those eligible, 14 (18.2%) received TC, with rates not different based on transplanted organ type ( p = 0.158) or whether they saw ID ( p = 0.273).
Conclusions
Despite the availability of vaccines, nearly 40% of pediatric solid organ transplant recipients remained unvaccinated against SARS‐CoV‐2 at time of the bivalent vaccine release. Less than a fifth of eligible patients received TC. Strategies to increase uptake of SARS‐CoV‐2 vaccines as well as adjunctive agents among this vulnerable group should be further explored.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID profiles: Christopher A Reis, Elizabeth H Ristagno, Theresa Madigan
Cite
APA
Reis, C. A., Ristagno, E. H., & Madigan, T. (2024). SARS‐CoV‐2 Vaccination Rates and Uptake of Tixagevimab‐Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients. Clinical Transplantation, 38(7). https://doi.org/10.1111/ctr.15407
Vancouver
Reis CA, Ristagno EH, Madigan T. SARS‐CoV‐2 Vaccination Rates and Uptake of Tixagevimab‐Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients. Clinical Transplantation. 2024;38(7). doi:10.1111/ctr.15407
BibTeX
@article{Reis2024,
author = {Reis, Christopher A and Ristagno, Elizabeth H and Madigan, Theresa},
title = {SARS‐CoV‐2 Vaccination Rates and Uptake of Tixagevimab‐Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients},
journal = {Clinical Transplantation},
year = {2024},
volume = {38},
number = {7},
doi = {10.1111/ctr.15407}
}
EUVIMED